Metoclopramide Accord (Metoclopramide Hydrochloride)

Metoclopramide blocks dopamine D2 receptors in the chemoreceptor trigger zone, lowering the central drive to vomit, while simultaneously increasing acetylcholine release in the gut, which enhances coordinated smooth‑muscle contractions and speeds gastric emptying.

The appropriate dose of metoclopramide is determined by the prescribing clinician based on the specific indication, patient age, renal function and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for metoclopramide in pregnancy and lactation are limited. It is classified as pregnancy category unknown, so clinicians must evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide is a dopamine D2 antagonist with pro‑kinetic activity, distinguishing it from pure serotonin antagonists such as ondansetron. It is particularly useful when delayed gastric emptying contributes to nausea, whereas other antiemetics may lack this motility‑enhancing effect.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Metoclopramide Accord is administered orally. The tablet (or other oral dosage form) should be swallowed with water, preferably before meals or as directed by the prescriber, to achieve optimal anti‑nausea and pro‑kinetic effects.

Serious adverse reactions include extrapyramidal symptoms such as acute dystonia, tardive dyskinesia with long‑term use, and neuroleptic malignant syndrome. Patients should be monitored for muscle rigidity, involuntary movements, fever or altered mental status, and the drug should be discontinued if these occur.

Metoclopramide should be avoided in individuals with known hypersensitivity to the drug, in patients with pheochromocytoma, and in those with a history of severe extrapyramidal reactions. Caution is also advised for patients with significant renal impairment or uncontrolled depression.